Literature DB >> 11568856

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.

S M Clarke1, F M Mulcahy, J Tjia, H E Reynolds, S E Gibbons, M G Barry, D J Back.   

Abstract

Administration of nevirapine to HIV-infected injection drug users who also receive methadone results in a significant reduction in methadone exposure after 7-10 days of therapy. Many patients require an increase in methadone dose to counteract this effect.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11568856     DOI： 10.1086/322519

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  25 in total

Review 1.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Drug interactions with antiretrovirals.

Authors:  Linda M Catanzaro; Judianne C Slish; Robert DiCenzo; Gene D Morse
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

Review 3.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 4.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Methadone for Pain Management: A Pharmacotherapeutic Review.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

Review 6.  Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Authors:  Yu Gao; John C Kraft; Danni Yu; Rodney J Y Ho
Journal:  Eur J Pharm Biopharm       Date:  2018-04-17       Impact factor: 5.571

7.  Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Authors:  Neill J Liptrott; Sudeep Pushpakom; Christoph Wyen; Gerd Fätkenheuer; Christian Hoffmann; Stefan Mauss; Heribert Knechten; Norbert H Brockmeyer; Elizabeth Hopper-Borge; Marco Siccardi; David J Back; Saye H Khoo; Munir Pirmohamed; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

8.  Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  J Pharm Pharmacol       Date:  2009-04       Impact factor: 3.765

9.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Authors:  Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790

10.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.